secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001641172-25-010895
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx Q1 revenue ~$200K from RenovoCath sales; TIGeR-PaC trial 91 patients randomized
--------------------------------------------------------------------------------

- Q1 2025 revenue of ~$200K from commercial RenovoCath sales, exceeding internal expectations; gross profit $103K.
- Cash $14.6M as of Mar 31, 2025, up from $7.2M at Dec 31, 2024; funds commercial scale-up and trial completion.
- Phase III TIGeR-PaC trial: 91 patients randomized, 56 events (second interim analysis triggered); DMC review expected Q3 2025.
- Net loss $2.4M vs $1.1M in Q1 2024 due to higher operating costs and lower warrant liability gain.
- Management and Board purchased ~143K shares; new U.S. patent issued for TAMP platform (19 patents total).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000164117225010895/0001641172-25-010895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000164117225010895/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer